Third Straight Pharma Buy Queue in Under a Week: IRDR Hits a One Year High on a 19 Session Run With No Price Moving Codal Disclosure Behind It (Monday, August 24, 2026)

Tehran Stock Exchange ticker IRDR (Iran Daru) closed up 2.94% on Monday, August 24, 2026, ending the session in a buy queue at 14,000 rials: its 19th consecutive higher close and a fresh one year high. This is the third time in under a week that a Tehran pharmaceutical ticker has strung together a run of buy queues like this, after Razak (DRAZK) (up nearly 176%) and Jaber Ebn Hayan (DJBR) (10 sessions, also today). But IRDR carries one important difference: per Sahmino's own check of Codal, the company has filed no price moving material disclosure (tier A or tier B forms) in the past 90 days, and has held no shareholder assembly in the past 365 days.

Background

Sahmino's trading data shows the current run began precisely on July 27, 2026, one day after a brief trading halt on July 26; that day's close was 8,290 rials, and from that session to today, without a single down day, the stock has gained 68.9% to reach 14,000 rials. Before that, IRDR's last negative session was June 28, 2026, closing at 5,290 rials. Over the trailing one year window (August 25, 2025 to August 24, 2026), the stock has risen from 2,798.70 rials to 14,000 rials, a 400.23% gain, and its one year closing low was 2,572.58 rials on September 24, 2025, meaning today's price stands 444.2% above that low and closed exactly at its one year high.

The numbers

• Today's close (August 24, 2026): 14,000 rials, up 2.94% (400 rials) from yesterday's close of 13,600 rials; a one year high (source: Tehran Stock Exchange official board and Sahmino's own trading board)
• The run: 19 consecutive higher closes, from 8,290 rials on July 27 to 14,000 rials on August 24, 2026, a gain of 68.9%
• Today's volume: 91,987,666 shares, 5.97 times the 20 session average; trade value of roughly 128.8 billion tomans across 2,425 trades
• Closing buy queue: unmet demand for 109,226 shares at 14,000 rials, with zero matching supply at the close
• Market capitalization at today's close: roughly 2,492 billion tomans (on 1,780,000,000 shares)
• IRDR's P/E, per Sahmino's nightly reading (as of August 22, 2026): 9.14, against the pharmaceutical products sector average of 12.98; free float 49%
• Trailing twelve month operating revenue through June 21, 2026: 1,318.2 billion tomans, up 166.79% year on year; trailing net profit 272.6 billion tomans; net margin 20.68% and return on equity (ROE) 57.47% (source: the audited six month interim financial statements, filed on Codal on August 19, 2026)

What is driving it

Unlike DJBR, whose rally coincided with a 16.58% block trade in its shareholder register, and Razak, whose rally coincided with a reported quarterly profit jump, Sahmino's search of Codal found no price moving material disclosure (tier A or tier B forms) for IRDR in the past 90 days, and no assembly decision (cash dividend or capital increase) in the past 365 days. The only other Codal letter on record for IRDR in this window is a routine notice introducing a change in the company's board of directors or CEO, filed on August 10, 2026; Sahmino has not yet read this letter's content in structured form, and in any case it was filed 14 days after the rally began on July 27, so it does not explain the rally's starting point. The only dated financial document behind this rally is that August 19 interim statement showing 166.79% revenue growth; the year on year net profit growth figure is not yet available in Sahmino's nightly computation, because the comparison period has not been published yet.

Today's board data shows the buying pressure came mainly from retail investors: retail buy volume of 87,396,010 shares against retail sell volume of 63,651,394 shares, a net retail inflow of 23,744,616 shares in this session alone; institutional investors were net sellers by the same amount. Per Sahmino's data, the estimated net retail inflow into this ticker over the past five sessions (a rial value derived from each day's volume and closing price) has been approximately 33 billion tomans.

Outlook

Whether this run continues hinges on two open questions that have no official answer yet: first, whether the company or its major shareholders will soon disclose what is actually driving this demand, or whether this is, like many undisclosed buy queue runs, simply a wave of retail liquidity and momentum that stops at the first session without a buy queue; second, whether IRDR's current P/E of 9.14, still below the pharmaceutical sector's 12.98 average, leaves room for further gains, or is low only because this fiscal year's profit growth is not yet fully reflected in its trailing twelve month EPS. Per Sahmino's composite ranking, IRDR scores 63 out of 100 and ranks fifth among the 63 tickers in the pharmaceutical products sector; that score and rank are Sahmino's own proprietary measures, not a figure the Tehran Stock Exchange itself publishes. Until more is officially disclosed, any forecast about the rally's continuation remains an estimate.

Bottom line

IRDR closed on Monday, August 24, 2026 with its 19th consecutive higher close, hit a one year high of 14,000 rials, and its market capitalization reached roughly 2,492 billion tomans; the key point is that unlike its two recent pharmaceutical peers, Razak and DJBR, this rally is not backed by any price moving Codal disclosure, and the only financial document behind it is a 166.79% revenue growth figure from the August 19 interim report. Until the company or its shareholders explain the demand, that official silence about the price driver, alongside the buy queue, remains this ticker's most notable feature.

What to watch

Three things are worth tracking in the coming days: whether IRDR files a price moving material disclosure on Codal, whether the buy queue holds or breaks in Tuesday's session on August 25, and whether the pharmaceutical sector's monthly activity report for the Iranian month of Shahrivar shows this same three ticker buy queue pattern, seen now in DJBR, Razak and IRDR, spreading to other pharmaceutical names.